How Is Tysabri-Related PML Diagnosed?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding how PML is diagnosed is critical. The medical community has developed a structured diagnostic process based on patterns reported in the literature. This page explains the key steps and considerations involved in confirming a PML diagnosis.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically addressing this risk. The boxed warning states that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three primary risk factors for developing PML: the presence of anti-JCV antibodies, the duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against the expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Mechanistic Pathway

PML is a demyelinating disease caused by the JC polyomavirus (JCV), primarily affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). The clinical presentation can vary but often includes progressive neurological deficits. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These trial data underscore that PML can develop even with relatively short exposure, though longer duration of therapy is a known risk factor. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for multiple sclerosis, but it also impairs immune surveillance against JCV. In the setting of reduced immune monitoring, latent JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML.

Risk Factors and Monitoring Requirements

The FDA Adverse Event Reporting System (FAERS) database lists numerous adverse events associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not establish causation, they reflect the range of neurological symptoms that may be reported by patients. Importantly, symptoms of PML can overlap with those of multiple sclerosis relapse, making diagnosis challenging. The boxed warning emphasizes that healthcare professionals should consider PML in any patient presenting with new neurological signs. From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The FDA boxed warning is explicit about the risk and the need for monitoring, and Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are informed of the risks and that prescribers adhere to monitoring protocols. However, questions may arise about whether patients were adequately warned before treatment initiation, particularly regarding the specific risk factors and the potential for severe outcomes.

Legal Considerations for Affected Patients

For patients who develop PML after Tysabri treatment, legal considerations may include whether the prescribing physician or the manufacturer provided sufficient information about the risk. The timeline between exposure and documented harm is variable. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with longer treatment duration, particularly beyond two years. Patients who develop PML often face severe disability or death, and the condition requires immediate discontinuation of Tysabri and supportive care. Attorney-related considerations for affected patients include the need to document the timing of Tysabri exposure, the presence of risk factors such as anti-JCV antibody status, and any prior immunosuppressant use. Medical records should be reviewed to determine whether monitoring for PML was conducted according to guidelines. The boxed warning mandates that Tysabri be withheld at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis or failure to act on early symptoms may be relevant in legal evaluations. In summary, the evidence establishes a clear link between Tysabri and PML, with specific risk factors and a mandated monitoring protocol. Patients who suffer harm may have grounds to seek legal counsel to evaluate whether adequate warnings were provided and whether appropriate clinical actions were taken.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It carries a boxed warning from the FDA for increased risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The risk is higher with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

PML symptoms include progressive neurological deficits such as weakness, vision changes, confusion, and coordination problems. Diagnosis involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Because symptoms can mimic multiple sclerosis relapse, healthcare professionals must consider PML in any patient on Tysabri presenting with new neurological signs (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options are available for patients who developed PML after Tysabri?

Patients who developed PML after Tysabri may seek legal counsel to evaluate whether they received adequate warnings about the risk and whether monitoring protocols were followed. Legal claims may involve failure to warn, negligence, or product liability. It is important to document treatment history, risk factors, and any delays in diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.